M&A / Deals Angelini inks $4.1B Catalyst buy to enter US rare disease market BioSpaceCatalyst Pharmaceuticals comes with a trio of approved drugs as Angelini Pharma expands its neuroscience offerings.Rare DiseaseRead full story pharminent May 7, 2026 (Last updated: May 7, 2026) BioSpace Catalyst Pharmaceuticals comes with a trio of approved drugs as Angelini Pharma expands its neuroscience offerings. Rare Disease Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Bayer plans filings for cardiac amyloidosis imaging agentNext: Novo’s CEO champions “record-breaking start” for Wegovy pill in US market Related Stories M&A / Deals Teva and Polpharma Biologics sign global deal for ocrelizumab biosimilar pharminent July 10, 2026 M&A / Deals GSK ends dementia alliance with Alector after setbacks pharminent July 9, 2026 M&A / Deals AstraZeneca, GSK intensify China ties with Sino Biopharm deals pharminent July 8, 2026
